HAEMATOKINE Trademark
HAEMATOKINE is a USPTO trademark filed by Faron Pharmaceuticals Oy. Status: Registered.
Trademark Facts
| Mark | HAEMATOKINE |
|---|---|
| Serial Number | 79313038 |
| Registration Number | 6823077 |
| Status | Registered |
| Filing Date | 2021-02-05 |
| Registration Date | 2022-08-23 |
| Mark Type | Word |
| Nice Classes | 001 (Chemicals), 005 (Pharmaceuticals) |
| Owner | Faron Pharmaceuticals Oy |
| Attorney of Record | Mark E. Olds |
| Prosecution Events | 36 |
| Latest Event | NREP on 2025-09-26 |
Goods & Services
Chemicals for use in industry, science and photography, as well as in agriculture, horticulture and forestry, except fungicides, herbicides, insecticides and parasiticides; Biological preparations for use in industry and science; Media for cell culture for use in the biotechnological industry, namely, cell culture media for scientific and research use; Media for cell culture for use in non-medical research laboratories, namely, cell culture media for laboratory use; Biological preparation for use in cell cultures other than for medical or veterinary use; Culture media for microbiology, for scientific and research use; Cell growth media for growing cells for scientific use; Biological preparation for use in cell cultures, other than for medical or veterinary use; Cultures of cell media other than for medical or veterinary use, namely culture media for scientific and research use; Cultures of microorganisms, other than for medical and veterinary use; Blood culture media being cell culture media for scientific use; Biological preparations for use in cell cultures, other than for medical or veterinary purposes; Stem cells, other than for medical or veterinary purposes; Stem cells for scientific purposes; Stem cells for research purposes | Pharmaceuticals, medical and veterinary preparations for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Sanitary preparations for medical purposes; Stem cells for medical or veterinary use; Stem cells for medical purposes; Tumor suppressing agents; Pharmaceutical preparations, namely, antineoplastics; Anti-neoplastic preparations of chemical origin, namely, pharmaceutical preparations for hematological malignancies, bone marrow dysfunction or suppressions; Anti-neoplastic preparations of microbial origin, namely, pharmaceutical preparations for hematological malignancies, bone marrow dysfunction or suppressions; Anti-cancer preparations; Compounds for treating cancer, namely, anti-cancer preparations; Antibodies for medical purposes for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Antibodies for medical use to treat inflammation and cancer growth and spread; Adjuvants for medical purposes; Vaccine adjuvants; Biological adjuvants for medical purposes; Anti-inflammatories; Antigens, namely, tumour antigens for medical diagnostic purposes; Biological preparations for the treatment of cancer; Biopharmaceuticals for the treatment of cancer; Biotechnological preparations for medical use, namely, biological preparations for the treatment of conditions associated with poor production of hematopoietic stem cells; Culture media for medical use, namely, culture media for use in augmentation of blood cells, bone marrow and tissues for medical purposes; Media for bacteriological cultures; Cell growth media for growing cells for medical use; Biological preparations for medical purposes, namely, biological preparations for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Mixed biological preparations for medical purposes, namely, mixed biological preparations for the prevention and treatment of infectious diseases; Biological preparations for veterinary purposes, namely, biological preparations for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Pharmaceutical preparations, namely, immunomodulators; Immunostimulants; Injectable pharmaceuticals for treatment of hematological malignancies, bone marrow dysfunction or suppressions; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of bone diseases; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for activating cellular function; Pharmaceutical preparations for immunity adjustment; Pharmaceutical preparations for regulating the immune system; Pharmaceutical preparations for treating malignant tumors; Pharmaceutical preparations for suppressing tumors; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the prevention of tumours; Pharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations and substances with anti-inflammatory properties for treatment of hematological malignancies, bone marrow dysfunction or suppressions; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the treatment of autoimmune disorders; Pharmaceutical preparations for use in hematology; Pharmaceutical preparations for the prevention of diseases of the immune system; Pharmaceutical preparations for the prevention of disorders of the immune system; Pharmaceutical preparations for the prevention of autoimmune diseases; Pharmaceutical preparations for the treatment of disorders caused by bacteria; Pharmaceutical preparations for the treatment of diseases caused by bacteria; Pharmaceutical preparations for the prevention of disorders of the respiratory system; Pharmaceutical preparations for the prevention of inflammatory disorders; Pharmaceutical preparations for the prevention of autoimmune disorders; Pharmaceutical preparations for the prevention of inflammatory diseases; Pharmaceutical preparations for the treatment of inflammatory diseases; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for use in tissue transplantation; Pharmaceutical products for the treatment of bone diseases; Regulatory proteins for medical use, namely, protein arrays for medical diagnosis purposes; Serotherapeutic medicines, namely, pharmaceutical preparations for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Synthetic peptides for pharmaceutical purposes for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Pharmaceutical products for treating respiratory diseases; Pharmaceutical compounds for treating respiratory diseases; Pharmaceutical preparations for treating respiratory diseases; Pharmaceutical compounds for treating correlated pulmonary syndromes; Pharmaceutical preparations for treatment and prevention of ischemic conditions, inflammation and organ damages resulting from tissue traumas, reperfusion injuries, cancer, cancer metastasis, inflammatory conditions and allergic conditions; Pharmaceutical preparations for treatment and prevention of multi-organ failure, acute lung injury and acute respiratory distress syndrome in adults, adolescents, children, infants and neonates